Simulations Plus, Inc. - SLP STOCK NEWS

Simulations Plus, Inc. (Nasdaq: SLP) reported its third quarter fiscal 2021 results with total revenue of $12.8 million, up 4% year-over-year. Software revenue surged 21% to $8.3 million, while services revenue dropped 18% to $4.5 million. Gross profit rose 7% to $10.3 million, and net income increased 29% to $3.8 million. For the year-to-date, total revenue grew 14% to $36.6 million, bolstered by a 32% rise in software revenue. Despite project delays in services, the company anticipates full-year revenue growth of 5-10%.

Simulations Plus, Inc. (Nasdaq: SLP) announced it will release its financial results for Q3 of fiscal year 2021, ending May 31, 2021, on July 12, 2021, after market close. A conference call is scheduled for the same day at 4:15 p.m. Eastern Time, where stakeholders can register to participate. Simulations Plus has been a leader in modeling and simulation software for drug development and has served clients for over 25 years, providing solutions to major pharmaceutical and regulatory agencies globally.

Simulations Plus (Nasdaq: SLP) announced the release of IPFsym version 1A, a quantitative systems pharmacology software aimed at developing treatments for idiopathic pulmonary fibrosis (IPF). The software, sponsored by a leading pharmaceutical company, aims to enhance treatment options in a market worth over $2 billion. Key features include a virtual population of over 700 subjects and important biomarkers like forced vital capacity and high-resolution computed tomography. The company will also host a webinar for further insights on IPFsym.

Simulations Plus, Inc. (Nasdaq: SLP) announced that CEO Shawn O’Connor will participate in the Craig-Hallum 18th Annual Institutional Investor Conference on June 2, 2021. The conference will be virtual, featuring over 150 public companies and allowing institutional clients to engage in one-on-one 30-minute meetings. Attendance is by invitation only. Simulations Plus has been a leading provider of simulation software and consulting services for drug discovery for 25 years, serving clients across the globe.

Simulations Plus (Nasdaq: SLP) announced that CEO Shawn O’Connor will present at the 16th Annual Needham Virtual Technology and Media Conference on May 20, 2021, at 1:30 p.m. ET. CFO Will Frederick will also participate in one-on-one meetings throughout the day. This conference will feature presentations from over 350 public and private company management teams, providing an excellent opportunity for shareholders and investors.

For inquiries or to schedule meetings, contact Hayden IR at slp@haydenir.com. More details can be found on the Needham conference website.

Simulations Plus, Inc. (Nasdaq: SLP) announced that its common stock has been approved for trading on The Nasdaq Global Select Market effective May 13, 2021. This milestone reflects the company's successful growth investments that have enhanced its financial performance and global scale. CEO Shawn O’Connor highlighted that this step will increase visibility and liquidity for existing and future shareholders. Simulations Plus has been providing modeling and simulation solutions for over 25 years, serving clients in pharmaceutical and biotechnology sectors.

Simulations Plus, Inc. (Nasdaq: SLP) launched version 10.2 of its flagship machine learning platform, ADMET Predictor, now marketed as APX.2. This update introduces significant enhancements, including a High Throughput Pharmacokinetic (HTPK) Simulation Module, new dosing options, and improved mutagenic risk rules. The enhancements boost software performance, making it easier for pharmaceutical companies to predict drug properties. Dr. David Miller highlighted the software's expanded capabilities, while Dr. Eric Jamois noted increased revenue from the product line, indicating strong market adoption.

Simulations Plus, Inc. (Nasdaq: SLP) has renewed access to its DILIsym software platform for the U.S. Food and Drug Administration (FDA). This unlimited licensing package allows FDA employees across various divisions to utilize the software, enhancing drug safety assessments related to drug-induced liver injury (DILI). Key leaders in drug development will discuss the software's application in a panel on April 29, 2021. DILIsym aids in predicting DILI risk, guiding crucial drug development decisions, and has been utilized in several regulatory submissions.